FDA Approves LEVOTHYROXINE SODIUM — Fresenius Kabi USA, LLC

Fresenius Kabi USA, LLC announced the FDA approval of intravenous levothyroxine sodium, potentially resolving therapeutic gaps by offering a pre-filled intravenous alternative for hospitalized patients in need of thyroid hormone replacement. This clearance could provide a valuable infusion option for patients unable to tolerate oral formulations, allowing the manufacturer to capture share in the acute care setting.